Outlook Therapeutics prices USD 5 million registered direct offering at USD 0.59 per share

Outlook Therapeutics, Inc.

Outlook Therapeutics, Inc.

OTLK

0.00
  • Outlook Therapeutics priced a registered direct offering of 8,539,709 common shares to GMS Ventures at USD 0.59 per share.
  • Gross proceeds expected at USD 5 million; closing expected on or about May 29, 2026.
  • Net proceeds earmarked for working capital, general corporate purposes.
  • Agreed to reprice warrants for 15,488,570 shares held by GMS; weighted average exercise price cut to USD 0.59 from USD 1.78.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Outlook Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605281600PRIMZONEFULLFEED9728482) on May 28, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.